摘要
本文对阿莫西林－克拉维酸钾复合制剂在９名健康成人中进行药物代谢动力学和生物利用度研究。血浆中药物浓度分别用藤黄八叠球菌和克雷伯氏肺炎杆菌为检定菌（用井式琼脂平板法）测定阿莫西林和克拉维田钾。单剂量口服２５０ｍｇ阿莫西林和１２５ｍｇ克拉维酸钾后其阿莫西林的Ｔｍａｘ１．１７±０．３１ｈｆｏ０．９７±０．３３ｈ；Ｃｍａｘ３．５±０．６μｇ／ｍｌ和３．６±０．７μｇｍｌ；Ｔ１／２１．１±０．３ｈ和１．１５±０．２７ｈ。克拉维酸钾为：Ｔｍａｘ１．ｌｌ±０．２４ｈ和０．８９±０．２９ｈ；Ｃｍａｘ３．６±１．０μｇ／ｍｌ和４．０±１．４４μｇ／ｍｌ；Ｔ１／２０．７８±０．１９ｈ和０．８±０．４ｈ。颗粒剂的相对生物利用度阿莫西林为１０４±２０％，克拉维酸钾为１０８±１１％。
moxicillin co-formulation is a new antibacterial agent in which clavulanic acid is a new β-lactamase inhibitor.In this paper ,microbiological assay was described. Amoxicillin was detected by a hole-in-plate with sarciva lutea asthe test organism. Clavulanic acid was determined with klebsiella pneumoniae 41164 as the test organism. The phar-macokinetics of single dose of amoxicillin at 250 mg after orall administration were Tmax 1. 17h and 0. 97h,Cmax3. 5ug/ml and 3. 6ug/ml ,T1/2 1. 10h and 1.15h (tablets and granules) . Pharmacokinetic parameters of clavulanic acid at125mg after orall administration were Tmax 1. 11h and 0. 89h, Cmax 3. 6ug/ml and 4.0ug/ml, T1/20. 78h and 0. 84h(tablets and granules). The relative bioavailability of AMX and CAV granules formulation was 104±20% and 108±11%, respectively.
出处
《中国医院药学杂志》
CAS
CSCD
北大核心
1996年第5期197-199,共3页
Chinese Journal of Hospital Pharmacy
